Comparative Pharmacology
Head-to-head clinical analysis: CHLORAMPHENICOL versus CHLOROPTIC S O P.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORAMPHENICOL versus CHLOROPTIC S O P.
CHLORAMPHENICOL vs CHLOROPTIC S.O.P.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
50-100 mg/kg/day IV divided every 6 hours (not to exceed 4 g/day); for susceptible severe infections, 12.5-25 mg/kg IV every 6 hours.
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
None Documented
None Documented
1.5-4.0 hours in adults; prolonged to 3-7 hours in neonates and up to 24 hours in severe hepatic impairment
Clinical Note
moderateChloramphenicol + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Chloramphenicol."
Clinical Note
moderateChloramphenicol + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Chloramphenicol."
Clinical Note
moderateChloramphenicol + Ketoconazole
"The metabolism of Ketoconazole can be decreased when combined with Chloramphenicol."
Clinical Note
moderateChloramphenicol + Ticlopidine
Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections
~90% renal (5-10% unchanged; remainder as inactive glucuronide), ~10% biliary/fecal
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Category D/X
Category C
Antibiotic
Antibiotic
"The metabolism of Ticlopidine can be decreased when combined with Chloramphenicol."